

Ellen H W Kapiteijn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4700721/publications.pdf>

Version: 2024-02-01

154
papers

11,711
citations

71102

41
h-index

28297

105
g-index

158
all docs

158
docs citations

158
times ranked

11753
citing authors

#	ARTICLE	IF	CITATIONS
1	Discontinuation of anti-PD-1 monotherapy in advanced melanoma” Outcomes of daily clinical practice. <i>International Journal of Cancer</i> , 2022, 150, 317-326.	5.1	12
2	The unfavorable effects of COVID-19 on Dutch advanced melanoma care. <i>International Journal of Cancer</i> , 2022, 150, 816-824.	5.1	18
3	Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer. <i>PLoS ONE</i> , 2022, 17, e0261939.	2.5	2
4	Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). <i>Clinical Colorectal Cancer</i> , 2022, 21, 154-166.	2.3	6
5	The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review. <i>Diagnostics</i> , 2022, 12, 715.	2.6	4
6	Health-Related Quality of Life in Adrenocortical Carcinoma: Development of the Disease-Specific Questionnaire ACC-QOL and Results from the PROFILES Registry. <i>Cancers</i> , 2022, 14, 1366.	3.7	0
7	Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study. <i>European Journal of Cancer</i> , 2022, 167, 70-80.	2.8	19
8	A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 515-524.	4.5	9
9	The gap between rare and common cancers still exists: Results from a population-based study in the Netherlands. <i>European Journal of Cancer</i> , 2022, 167, 103-111.	2.8	10
10	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. <i>Nature Medicine</i> , 2022, 28, 1178-1188.	30.7	121
11	Management of checkpoint inhibitor toxicity and survival in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9546-9546.	1.6	0
12	Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. <i>Melanoma Research</i> , 2022, 32, 460-468.	1.2	7
13	Safety and efficacy of combined melphalan percutaneous hepatic perfusion (M-PHP) and ipilimumab plus nivolumab (IPI+NIVO) in metastasized uveal melanoma (mUM): First results of the phase Ib part of the CHOPIN trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9560-9560.	1.6	0
14	Adjuvant treatment of in-transit melanoma: Addressing the knowledge gap left by clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9577-9577.	1.6	0
15	The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9605-TPS9605.	1.6	19
16	Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9501-9501.	1.6	12
17	Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 1130-1141.	1.5	19
18	Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study. <i>British Journal of Cancer</i> , 2021, 124, 1199-1206.	6.4	12

#	ARTICLE	IF	CITATIONS
19	First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. <i>British Journal of Cancer</i> , 2021, 124, 1222-1230.	6.4	16
20	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. <i>Hepatology International</i> , 2021, 15, 510-519.	4.2	14
21	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3123-3135.	4.2	6
22	Phase Ib/randomized phase II study combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: The CHOPIN trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS9595-TPS9595.	1.6	0
23	Is adjuvant treatment for melanoma in clinical practice comparable to trials? The first population-based results.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21523-e21523.	1.6	0
24	Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nationwide quality assurance in the Netherlands.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18641-e18641.	1.6	0
25	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 641-648.	3.9	46
26	Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants. <i>Cancers</i> , 2021, 13, 2440.	3.7	6
27	<i>BRAF</i> and <i>NRAS</i> mutation status and response to checkpoint inhibition in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9558-9558.	1.6	0
28	Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9544-9544.	1.6	0
29	Dutch advanced melanoma care in times of COVID-19.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21502-e21502.	1.6	1
30	Efficacy of checkpoint inhibition in advanced acral melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21527-e21527.	1.6	0
31	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2826.	3.7	11
32	Targeting EML4-ALK gene fusion variant 3 in thyroid cancer. <i>Endocrine-Related Cancer</i> , 2021, 28, 377-389.	3.1	16
33	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021, 151, 72-83.	2.8	12
34	Nanocarriers as a Tool for the Treatment of Colorectal Cancer. <i>Pharmaceutics</i> , 2021, 13, 1321.	4.5	13
35	Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1031-1038.	1.0	2
36	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. <i>Cancers</i> , 2021, 13, 4639.	3.7	9

#	ARTICLE	IF	CITATIONS
37	Adjuvant treatment for melanoma in clinical practice – Trial versus reality. <i>European Journal of Cancer</i> , 2021, 158, 234-245.	2.8	12
38	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 1345-1346.	3.9	4
39	Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 82-89.	1.3	2
40	Hospital Variation in Cancer Treatments and Survival Outcomes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. <i>Cancers</i> , 2021, 13, 5077.	3.7	1
41	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. <i>Melanoma Research</i> , 2021, 31, 58-66.	1.2	6
42	Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 6366.	3.7	10
43	Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutations. <i>Journal of Medical Genetics</i> , 2020, 57, 316-321.	3.2	33
44	A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature. <i>Familial Cancer</i> , 2020, 19, 15-21.	1.9	8
45	The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review. <i>International Journal of Cancer</i> , 2020, 146, 1479-1489.	5.1	20
46	Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). <i>Melanoma Research</i> , 2020, 30, 252-260.	1.2	37
47	Malignant pheochromocytoma and paraganglioma: management options. <i>Current Opinion in Oncology</i> , 2020, 32, 20-26.	2.4	28
48	Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. <i>ESMO Open</i> , 2020, 5, e000945.	4.5	14
49	Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands – A nationwide population-based study. <i>European Journal of Cancer</i> , 2020, 137, 127-135.	2.8	14
50	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. <i>Cancers</i> , 2020, 12, 2072.	3.7	16
51	Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study. , 2020, 8, e000166.		17
52	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176.	3.7	11
53	Real-world outcomes of advanced melanoma patients not represented in phase III trials. <i>International Journal of Cancer</i> , 2020, 147, 3461-3470.	5.1	27
54	Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2020, 6, 1300.	7.1	4

#	ARTICLE	IF	CITATIONS
55	Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1031-1039.	4.1	41
56	Hypocalcemia induced by tyrosine kinase inhibitors: targeted treatment with $\hat{\sim}$ untargeted $\hat{\sim}$ ™ side effects. <i>Acta Oncol³gica</i> , 2020, 59, 726-729.	1.8	4
57	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. <i>Cancers</i> , 2020, 12, 1003.	3.7	15
58	Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1 $\hat{\sim}$ Treated Patients in the Dutch Melanoma Treatment Registry. <i>Clinical Cancer Research</i> , 2020, 26, 2268-2274.	7.0	112
59	Multicentre study of short-course radiotherapy, systemic therapy and resection/ablation for stage IV rectal cancer. <i>British Journal of Surgery</i> , 2020, 107, 537-545.	0.3	15
60	Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. , 2020, 8, e001607.		4
61	First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10002-10002.	1.6	57
62	Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. <i>European Journal of Endocrinology</i> , 2020, 182, 131-138.	3.7	36
63	Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades. <i>European Journal of Endocrinology</i> , 2020, 183, 203-209.	3.7	21
64	Real-world outcomes of advanced melanoma patients not represented in phase III trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10042-10042.	1.6	1
65	Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10032-10032.	1.6	0
66	Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 250-264.	0.7	4
67	Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial. <i>BMJ Open</i> , 2020, 10, e044036.	1.9	0
68	Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial. <i>BMJ Open</i> , 2020, 10, e044036.	1.9	7
69	Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. <i>Journal of Geriatric Oncology</i> , 2019, 10, 389-397.	1.0	20
70	Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer. <i>Drugs and Aging</i> , 2019, 36, 927-938.	2.7	74
71	Metastatic Uveal Melanoma: Treatment Strategies and Survival $\hat{\sim}$ Results from the Dutch Melanoma Treatment Registry. <i>Cancers</i> , 2019, 11, 1007.	3.7	22
72	So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UMCU. <i>Cancers</i> , 2019, 11, 1032.	3.7	46

#	ARTICLE	IF	CITATIONS
73	Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. <i>Cancers</i> , 2019, 11, 845.	3.7	58
74	Targeted Treatment Options of Recurrent Radioactive Iodine Refractory H ¹²⁵ I Cell Cancer. <i>Cancers</i> , 2019, 11, 1185.	3.7	7
75	Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. <i>Cancers</i> , 2019, 11, 817.	3.7	11
76	Evolutionary Routes in Metastatic Uveal Melanomas Depend on <i>MBD4</i> Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 5513-5524.	7.0	46
77	Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems [™] Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 841-852.	2.0	28
78	Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program. <i>Journal of Immunotherapy</i> , 2019, 42, 208-214.	2.4	12
79	Embolization of variant hepatic arteries in patients undergoing percutaneous hepatic perfusion for unresectable liver metastases from ocular melanoma. <i>Diagnostic and Interventional Radiology</i> , 2019, 25, 451-458.	1.5	7
80	The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. <i>Nature</i> , 2019, 574, 127-131.	27.8	152
81	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. <i>Cancers</i> , 2019, 11, 1940.	3.7	29
82	Quality of Life After Curative Resection for Rectal Cancer in Patients Treated With Adjuvant Chemotherapy Compared With Observation: Results of the Randomized Phase III SCRIPT Trial. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 711-720.	1.3	7
83	Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature. <i>Cancer Treatment Reviews</i> , 2019, 73, 91-103.	7.7	37
84	Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2019, 7, 6-11.	3.4	118
85	Abstract CT068: A Phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma. <i>Cancer Research</i> , 2019, 79, CT068-CT068.	0.9	21
86	ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9599-TPS9599.	1.6	10
87	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9605-TPS9605.	1.6	16
88	Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2019, 180, 235-241.	3.7	28
89	Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 241-250.	3.1	20
90	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	10.7	183

#	ARTICLE	IF	CITATIONS
91	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 579-588.	1.4	11
92	Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 572-578.	1.4	11
93	Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. <i>International Journal of Clinical Oncology</i> , 2018, 23, 482-489.	2.2	34
94	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). <i>Journal of Clinical Oncology</i> , 2018, 36, 1232-1239.	1.6	207
95	Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. <i>The Cochrane Library</i> , 2018, 2018, CD012326.	2.8	5
96	Conjunctival Metastasis of a Cutaneous Melanoma. <i>Ocular Oncology and Pathology</i> , 2018, 4, 107-111.	1.0	10
97	Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. <i>Melanoma Research</i> , 2018, 28, 326-332.	1.2	8
98	A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6021-6021.	1.6	7
99	Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9579-9579.	1.6	1
100	Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2525.	3.6	55
101	Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. <i>Cancer Immunology Research</i> , 2017, 5, 170-179.	3.4	23
102	Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1196-1205.	2.0	19
103	Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands. <i>Acta Oncologica</i> , 2017, 56, 101-103.	1.8	39
104	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. <i>European Journal of Cancer</i> , 2017, 72, 156-165.	2.8	77
105	A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1447-1456.	3.5	17
106	Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver Malignancies. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 801-814.	2.0	32
107	Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	8
108	Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres. <i>Melanoma Research</i> , 2016, 26, 588-594.	1.2	17

#	ARTICLE	IF	CITATIONS
109	Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients. <i>Medicine (United States)</i> , 2016, 95, e3457.	1.0	30
110	Neoantigen landscape dynamics during human melanoma-T cell interactions. <i>Nature</i> , 2016, 536, 91-95.	27.8	387
111	Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 63-71.	2.3	34
112	(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. <i>BMC Cancer</i> , 2016, 16, 31.	2.6	6
113	Abstract PR11: Neo-antigen landscape dynamics during human melanoma-T cell interactions. , 2016, , .		0
114	Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-8.	1.5	42
115	Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. <i>Ophthalmology</i> , 2015, 122, 1907-1916.	5.2	69
116	THERAPY OF ENDOCRINE DISEASE: Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2015, 172, R215-R225.	3.7	60
117	Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer - TLC study. <i>Journal of Geriatric Oncology</i> , 2015, 6, 307-315.	1.0	15
118	Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. <i>Annals of Oncology</i> , 2015, 26, 696-701.	1.2	302
119	Anti-CTLA-4 therapy broadens the melanoma-reactive CD8 ⁺ T cell response. <i>Science Translational Medicine</i> , 2014, 6, 254ra128.	12.4	325
120	Preoperative Chemoradiation Therapy in Combination With Panitumumab for Patients With Resectable Esophageal Cancer: The PACT Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 190-196.	0.8	24
121	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 449-58.	4.2	253
122	Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 9030-9030.	1.6	38
123	Landscape of genetic alterations in patients with metastatic uveal melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 9043-9043.	1.6	11
124	Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer - the RAPIDO trial. <i>BMC Cancer</i> , 2013, 13, 279.	2.6	237
125	Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). <i>Acta Oncologica</i> , 2013, 52, 1786-1788.	1.8	67
126	Addition of interferon- γ to the p53-SLP α vaccine results in increased production of interferon- γ in vaccinated colorectal cancer patients: A phase I/II clinical trial. <i>International Journal of Cancer</i> , 2013, 132, 1581-1591.	5.1	50

#	ARTICLE	IF	CITATIONS
127	Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients – a large population-based study from 1990 to 2008. <i>Acta Oncologica</i> , 2013, 52, 941-949.	1.8	22
128	Serum lactate dehydrogenase (LDH) as a prognostic selection criterion for ipilimumab treatment in metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3036-3036.	1.6	2
129	Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. <i>European Journal of Endocrinology</i> , 2012, 167, 643-650.	3.7	113
130	Severe colitis while responding to ipilimumab in metastatic melanoma. <i>Acta Oncologica</i> , 2012, 51, 805-807.	1.8	8
131	New treatment modalities in advanced thyroid cancer. <i>Annals of Oncology</i> , 2012, 23, 10-18.	1.2	84
132	Genome Haploidisation with Chromosome 7 Retention in Oncocytic Follicular Thyroid Carcinoma. <i>PLoS ONE</i> , 2012, 7, e38287.	2.5	63
133	Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. <i>Clinical Investigation</i> , 2011, 1, 241-253.	0.0	3
134	Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 953-963.	4.2	69
135	Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3758-3762.	3.6	100
136	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2009, 161, 923-931.	3.7	223
137	Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukoencephalopathy syndrome. <i>Annals of Oncology</i> , 2007, 18, 1745-1747.	1.2	118
138	Radiation induces different changes in expression profiles of normal rectal tissue compared with rectal carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 127-135.	2.8	17
139	Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1311-1320.	0.8	253
140	Managing rectal cancer: the Dutch experience. <i>Colorectal Disease</i> , 2003, 5, 423-426.	1.4	11
141	Macroscopic Evaluation of Rectal Cancer Resection Specimen: Clinical Significance of the Pathologist in Quality Control. <i>Journal of Clinical Oncology</i> , 2002, 20, 1729-1734.	1.6	822
142	Acute Side Effects and Complications After Short-Term Preoperative Radiotherapy Combined With Total Mesorectal Excision in Primary Rectal Cancer: Report of a Multicenter Randomized Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 817-825.	1.6	255
143	The role of total mesorectal excision in the management of rectal cancer. <i>Surgical Clinics of North America</i> , 2002, 82, 995-1007.	1.5	55
144	Developments and quality assurance in rectal cancer surgery. <i>European Journal of Cancer</i> , 2002, 38, 919-936.	2.8	78

#	ARTICLE	IF	CITATIONS
145	Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. <i>British Journal of Surgery</i> , 2002, 89, 1142-1149.	0.3	441
146	p53 expression in human rectal tissue after radiotherapy: upregulation in normal mucosa versus functional loss in rectal carcinomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 720-728.	0.8	20
147	Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer. <i>New England Journal of Medicine</i> , 2001, 345, 638-646.	27.0	3,840
148	Mechanisms of oncogenesis in colon versus rectal cancer. <i>Journal of Pathology</i> , 2001, 195, 171-178.	4.5	166
149	European trials with total mesorectal excision. <i>Journal of Surgical Oncology</i> , 2000, 19, 350-357.	1.4	38
150	European trials with total mesorectal excision. <i>Journal of Surgical Oncology</i> , 2000, 19, 350-357.	1.4	5
151	Total Mesorectal Excision (TME) with or without Preoperative Radiotherapy in the Treatment of Primary Rectal Cancer: Prospective Randomised Trial with Standard Operative and Histopathological Techniques. <i>The European Journal of Surgery</i> , 1999, 165, 410-420.	0.9	241
152	Local recurrence in patients with rectal cancer diagnosed between 1988 and 1992: a population-based study in the west Netherlands. <i>European Journal of Surgical Oncology</i> , 1998, 24, 528-535.	1.0	170
153	Intermittent versus continuous systemic therapy as treatment for unresectable metastatic colorectal cancer. <i>The Cochrane Library</i> , 0, , .	2.8	0
154	Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. <i>The Cochrane Library</i> , 0, , .	2.8	0